Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 190.6 Million USD | 0.07% |
| 2023 | 248.52 Million USD | 10.38% |
| 2022 | 225.16 Million USD | 54.35% |
| 2021 | 145.88 Million USD | 15.07% |
| 2020 | 126.77 Million USD | 25.14% |
| 2019 | 101.3 Million USD | -29.28% |
| 2018 | 143.24 Million GBP | -1.18% |
| 2017 | 144.96 Million GBP | 20.89% |
| 2016 | 119.91 Million GBP | 56.95% |
| 2015 | 76.4 Million GBP | 11.05% |
| 2014 | 68.8 Million GBP | 26.47% |
| 2013 | 54.4 Million GBP | -10.53% |
| 2012 | 60.8 Million GBP | -10.46% |
| 2011 | 67.9 Million GBP | -15.13% |
| 2010 | 80 Million GBP | -9.09% |
| 2009 | 88 Million GBP | 13.55% |
| 2008 | 77.5 Million GBP | -31.05% |
| 2007 | 112.4 Million GBP | -7.79% |
| 2006 | 121.9 Million GBP | 1389.49% |
| 2005 | 8.18 Million GBP | 9.73% |
| 2004 | 7.45 Million GBP | -38.85% |
| 2003 | 12.19 Million GBP | -20.94% |
| 2002 | 15.42 Million GBP | -24.51% |
| 2001 | 20.43 Million GBP | -25.4% |
| 2000 | 27.39 Million GBP | 433.92% |
| 1999 | -8.2 Million GBP | 3.13% |
| 1998 | -8.46 Million GBP | 8.52% |
| 1997 | -9.25 Million GBP | -141.79% |
| 1996 | -3.82 Million GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 314.43 Million USD | 26.52% |
| 2024 Q3 | 190.6 Million GBP | -40.13% |
| 2024 Q1 | 238.59 Million GBP | -4.0% |
| 2024 Q2 | 318.37 Million GBP | 33.44% |
| 2024 Q4 | 190.6 Million GBP | 30.48% |
| 2023 Q3 | 185.8 Million GBP | -28.38% |
| 2023 Q4 | 248.52 Million USD | 33.76% |
| 2023 Q2 | 259.41 Million USD | 26.79% |
| 2023 FY | 248.52 Million USD | 10.38% |
| 2023 Q1 | 204.6 Million GBP | 10.59% |
| 2022 Q1 | 134.7 Million GBP | -7.66% |
| 2022 Q2 | 143.3 Million GBP | 6.38% |
| 2022 Q3 | 174.9 Million GBP | 22.05% |
| 2022 Q4 | 185 Million GBP | 5.77% |
| 2022 FY | 225.16 Million USD | 54.35% |
| 2021 Q3 | 96.6 Million GBP | -23.35% |
| 2021 Q4 | 145.88 Million GBP | 51.02% |
| 2021 Q1 | 83.2 Million GBP | -34.37% |
| 2021 Q2 | 126.03 Million GBP | 51.48% |
| 2021 FY | 145.88 Million USD | 15.07% |
| 2020 FY | 126.77 Million USD | 25.14% |
| 2020 Q1 | 99.7 Million GBP | -1.59% |
| 2020 Q4 | 126.77 Million GBP | 36.9% |
| 2020 Q3 | 92.59 Million GBP | -34.79% |
| 2020 Q2 | 142.01 Million GBP | 42.44% |
| 2019 Q3 | 77.4 Million GBP | -9.26% |
| 2019 FY | 101.3 Million USD | -29.28% |
| 2019 Q1 | 84.29 Million GBP | -22.3% |
| 2019 Q2 | 85.3 Million GBP | 1.19% |
| 2019 Q4 | 101.3 Million GBP | 30.89% |
| 2018 Q1 | 111.79 Million GBP | -7.83% |
| 2018 Q3 | 107.1 Million GBP | -5.56% |
| 2018 Q4 | 108.5 Million GBP | 1.31% |
| 2018 FY | 143.24 Million GBP | -1.18% |
| 2018 Q2 | 113.4 Million GBP | 1.43% |
| 2017 Q4 | 121.3 Million GBP | 10.07% |
| 2017 FY | 144.96 Million GBP | 20.89% |
| 2017 Q3 | 110.2 Million GBP | 1.1% |
| 2017 Q2 | 109 Million GBP | 1.49% |
| 2017 Q1 | 107.4 Million GBP | 12.46% |
| 2016 Q1 | 87.1 Million GBP | 14.01% |
| 2016 Q3 | 89.8 Million GBP | 1.81% |
| 2016 Q4 | 95.5 Million GBP | 6.35% |
| 2016 FY | 119.91 Million GBP | 56.95% |
| 2016 Q2 | 88.2 Million GBP | 1.26% |
| 2015 Q2 | 73.2 Million GBP | 1.53% |
| 2015 Q1 | 72.1 Million GBP | 4.8% |
| 2015 FY | 76.4 Million GBP | 11.05% |
| 2015 Q3 | 70.8 Million GBP | -3.28% |
| 2015 Q4 | 76.4 Million GBP | 7.91% |
| 2014 Q1 | 78.8 Million GBP | 44.85% |
| 2014 FY | 68.8 Million GBP | 26.47% |
| 2014 Q4 | 68.8 Million GBP | 9.21% |
| 2014 Q2 | 79.9 Million GBP | 1.4% |
| 2014 Q3 | 63 Million GBP | -21.15% |
| 2013 Q2 | 63.9 Million GBP | 0.0% |
| 2013 Q3 | 51.7 Million GBP | -19.09% |
| 2013 FY | 54.4 Million GBP | -10.53% |
| 2013 Q4 | 54.4 Million GBP | 5.22% |
| 2012 Q2 | 69.6 Million GBP | 0.0% |
| 2012 FY | 60.8 Million GBP | -10.46% |
| 2012 Q4 | 60.8 Million GBP | 0.0% |
| 2011 Q4 | 67.9 Million GBP | 0.0% |
| 2011 FY | 67.9 Million GBP | -15.13% |
| 2011 Q2 | 70.6 Million GBP | 0.0% |
| 2010 Q4 | 80 Million GBP | 0.0% |
| 2010 Q2 | 85.6 Million GBP | 0.0% |
| 2010 FY | 80 Million GBP | -9.09% |
| 2009 Q4 | 88 Million GBP | 0.0% |
| 2009 FY | 88 Million GBP | 13.55% |
| 2009 Q2 | 99.2 Million GBP | 0.0% |
| 2008 FY | 77.5 Million GBP | -31.05% |
| 2008 Q4 | 77.5 Million GBP | 0.0% |
| 2008 Q2 | 93.2 Million GBP | 0.0% |
| 2007 Q4 | 112.4 Million GBP | 0.0% |
| 2007 Q2 | 123.5 Million GBP | 0.0% |
| 2007 FY | 112.4 Million GBP | -7.79% |
| 2006 Q3 | -19.69 Million GBP | 0.0% |
| 2006 FY | 121.9 Million GBP | 1389.49% |
| 2006 Q1 | -4.29 Million GBP | 0.0% |
| 2005 FY | 8.18 Million GBP | 9.73% |
| 2005 Q1 | -4.72 Million GBP | 0.0% |
| 2005 Q3 | 8.18 Million GBP | 0.0% |
| 2004 FY | 7.45 Million GBP | -38.85% |
| 2004 Q3 | 7.45 Million GBP | 0.0% |
| 2004 Q1 | -4.58 Million GBP | 0.0% |
| 2003 FY | 12.19 Million GBP | -20.94% |
| 2002 FY | 15.42 Million GBP | -24.51% |
| 2001 FY | 20.43 Million GBP | -25.4% |
| 2000 FY | 27.39 Million GBP | 433.92% |
| 1999 FY | -8.2 Million GBP | 3.13% |
| 1998 FY | -8.46 Million GBP | 8.52% |
| 1997 FY | -9.25 Million GBP | -141.79% |
| 1996 FY | -3.82 Million GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 14549718.321% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -3274.425% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -345.4% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 76456.061% |
| Rebus Holdings, Inc. | 305 Thousand USD | -62391.803% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 3123.226% |
| Qrons Inc. | 351.42 Thousand USD | -54136.015% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -30525.165% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -338.827% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 934047.472% |
| Skye Bioscience, Inc. | -5.72 Million USD | 3431.359% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -1109.161% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -4528.433% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -47330.751% |
| SQZ Biotechnologies Company | -36.23 Million USD | 625.967% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -8400.455% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -20456.825% |
| Mesoblast Limited | 55.85 Million USD | -241.221% |
| Marizyme, Inc. | 18.56 Million USD | -926.44% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -8424.791% |
| Pharming Group N.V. | 109.8 Million USD | -73.582% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -22056.582% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -15601.613% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -27929.412% |
| ContraFect Corporation | -6.02 Million USD | 3262.961% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -141463.737% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -16396.037% |
| IMV Inc. | 7.67 Million USD | -2384.838% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -3364.26% |
| MultiCell Technologies, Inc. | 90.04 USD | -211683596.135% |
| ONE Bio Corp. | 9.04 Million USD | -2008.399% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 26068.081% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -1372.269% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -13833.044% |
| Q BioMed Inc. | 4.06 Million USD | -4594.572% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -523.814% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -18814.059% |
| Biomind Labs Inc. | 711.4 Thousand USD | -26692.165% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -214.803% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -9432.898% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -1388.296% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -52887.129% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -136233.724% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -959279.876% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -8555.842% |
| GB Sciences, Inc. | 1.74 Million USD | -10808.159% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 103806.444% |
| HST Global, Inc. | 96.79 Thousand USD | -196815.066% |
| CSL Limited | 10.52 Billion USD | 98.189% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -92326.91% |
| Halberd Corporation | 144.72 Thousand USD | -131601.688% |
| Enzolytics Inc. | 981.65 Thousand USD | -19316.17% |
| Agentix Corp. | 37.63 Thousand USD | -506397.303% |
| Resverlogix Corp. | 6.45 Million USD | -2854.581% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 28417.206% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 109.395% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 505.428% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -2595.528% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -6936.807% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 2256.13% |
| AVAX Technologies, Inc. | -5.9 Million USD | 3328.753% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1893779.173% |
| Genscript Biotech Corporation | -1.06 Billion USD | 117.959% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -94994.596% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -7888.151% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -115759.923% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1040606.606% |
| Kadimastem Ltd | -253.1 Thousand USD | 75405.608% |
| Helix BioMedix, Inc. | -2.57 Million USD | 7516.25% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -840.028% |
| BioStem Technologies, Inc. | 4.47 Million USD | -4162.065% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -94606.192% |
| LadRx Corporation | -2.03 Million USD | 9459.337% |
| Cell Source, Inc. | 9.23 Million USD | -1964.565% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -29907.856% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -29907.856% |
| NovAccess Global Inc. | 2.17 Million USD | -8649.28% |
| Affymax, Inc. | -5.59 Million USD | 3505.396% |
| Itoco Inc. | 228.3 Thousand USD | -83384.812% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -140058.395% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -3745.068% |
| Mobile Lads Corp. | 484.23 Thousand USD | -39261.298% |
| CytoDyn Inc. | 20.26 Million USD | -840.677% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 29459141.731% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 2056563.185% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -2373.397% |
| SYBLEU INC | 473.71 Thousand USD | -40135.247% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -4176.398% |
| International Stem Cell Corporation | 2.59 Million USD | -7259.073% |
| Bioxytran, Inc. | 1.89 Million USD | -9937.316% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -305285.096% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -8639.511% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -5450.379% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -2128.458% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -24569.722% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 15348.0% |
| Neutra Corp. | 52.18 Thousand USD | -365125.056% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 7757.694% |
| PureTech Health plc | -167.19 Million USD | 213.997% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 77925.143% |
| IXICO plc | -4.44 Million USD | 4388.362% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -1341.864% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -247.487% |
| CSL Limited | 10.52 Billion USD | 98.189% |
| Cellectis S.A. | -43.81 Million USD | 534.972% |